Drug intelligence / Profile preview

WT1-anchored Bifidobacterium longum 420

Development stage: Unknown
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**WT1-anchored Bifidobacterium longum 420** is a genetically engineered oral protein vaccine platform, developed by anchoring the Wilms’ tumor 1 (WT1) protein, a tumor-associated antigen, onto the probiotic bacterium *Bifidobacterium longum* 420. This oral vaccine aims to induce intestinal immunity against cancer, particularly showing antitumor activity by activating WT1-specific immune responses. Oral administration of this vaccine in preclinical mouse models demonstrated significant tumor size reduction and activation of CD8+ T cells, along with enhanced activation of dendritic cells and increased production of WT1-specific antibodies. The vaccine uses the mucosal immune system via Peyer’s patches to prime systemic antitumor immunity, suggesting a novel intestinal bacterium-based cancer immunotherapy approach. This platform leverages the natural probiotic properties of *B. longum* 420 alongside engineered cancer antigen presentation to stimulate an effective antitumor immune response.

Targets

CD8A (CD8 alpha/beta Coreceptor)

Beyond the preview

Go deeper on WT1-anchored Bifidobacterium longum 420.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WT1-anchored Bifidobacterium longum 420.

Explore the full profile